

CP-SCD Announces Pfizer Executive as its First Industry Co-Director



C-Path's Critical Path to Sickle Cell Disease Consortium (CP-SCD) is pleased to announce Dr. David Readett of Pfizer as its first Industry Co-Director. David is a pediatrician/pediatric hematologist/oncologist who, prior to transitioning to clinical research in the pharmaceutical industry, spent 18 years in clinical practice, with a focus on clinical care and research for pediatric patients with oncologic or hematologic disease, including sickle cell disease. His experience in the pharmaceutical industry has been in oncology/hematology clinical drug development with his penultimate role focused exclusively on sickle cell. Dr. Readett has been with Pfizer since 2004 and spent the last several years within their rare disease group where he was the Global Clinical Lead for the Rivipansel program. The CP-SCD team is grateful to be working with Dr. Readett and welcomes him to the team. Learn more about CP-SCD at <https://c-path.org/programs/cp-scd/>.